Core Insights - Cullinan Therapeutics announced that the Phase 2b portion of the REZILIENT1 study met its primary endpoint of overall response rate for zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations [1][2] - The results will be presented at the 2025 ASCO Annual Meeting, highlighting the potential of zipalertinib to address significant unmet needs in this patient population [1][2] Study Details - The presentation will focus on the efficacy of zipalertinib in NSCLC patients who have received prior platinum-based chemotherapy, with or without amivantamab [3] - The presentation is scheduled for June 1, 2025, from 8:00 AM to 11:00 AM CDT, with an abstract number of 8503 [3] Investor Engagement - Cullinan will host an in-person event for analysts and institutional investors on June 1, 2025, at 6:30 PM CDT to discuss the zipalertinib data [3][4] - Registration for the event is available via email, and a webcast will be accessible on the company's investor relations website [4] Product Information - Zipalertinib is an orally available small molecule targeting activating mutations in EGFR, specifically designed to inhibit EGFR variants with exon 20 insertion mutations [5] - The drug has received Breakthrough Therapy Designation from the FDA, indicating its potential significance in treating a genetically defined subset of NSCLC patients [5][6] Company Overview - Cullinan Therapeutics is focused on developing new standards of care for patients, with a diversified portfolio of clinical-stage assets targeting key disease drivers [7][8] - The company emphasizes a rigorous development process to fast-track promising therapeutic candidates across various indications, including cancer and autoimmune diseases [8]
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025